+11.9%
ACN vs MRNA
+945.0%
-933.1%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.8% | +13.1% | -9.3% | +3.5% |
| 7D | +8.6% | +20.6% | -12.1% | +8.0% |
| 30D | +36.6% | +27.1% | +9.4% | +35.4% |
| 3M | +56.3% | +353.4% | -297.1% | +45.8% |
| 6M | +49.7% | +446.3% | -396.6% | +39.9% |
| YTD | +1.3% | +776.2% | -774.8% | -6.2% |
| 1Y | +11.9% | +987.9% | -976.0% | +3.5% |
| All | +11.9% | +945.0% | -933.1% | +3.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling